These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 9652560)

  • 1. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus.
    Acerini CL; Patton CM; Savage MO; Kernell A; Westphal O; Dunger DB
    Lancet; 1997 Oct; 350(9086):1199-204. PubMed ID: 9652560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of repeated daily recombinant human insulin-like growth factor I administration in adolescents with type 1 diabetes.
    Cheetham TD; Holly JM; Clayton K; Cwyfan-Hughes S; Dunger DB
    Diabet Med; 1995 Oct; 12(10):885-92. PubMed ID: 8846679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of HbA1c without increased hypoglycemia in adolescents and young adults with type 1 diabetes mellitus treated with recombinant human insulin-like growth factor-I and insulin. rhIGF-I in IDDM Study Group.
    Quattrin T; Thrailkill K; Baker L; Kuntze J; Compton P; Martha P;
    J Pediatr Endocrinol Metab; 2001 Mar; 14(3):267-77. PubMed ID: 11308044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system.
    Thrailkill K; Quattrin T; Baker L; Litton J; Dwigun K; Rearson M; Poppenheimer M; Kotlovker D; Giltinan D; Gesundheit N; Martha P
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1181-7. PubMed ID: 9100593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IGF-I and diabetes in adolescence.
    Dunger DB; Acerini CL
    Diabetes Metab; 1998 Apr; 24(2):101-7. PubMed ID: 9592633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between overnight GH levels and insulin concentrations in adolescents with insulin-dependent diabetes mellitus (IDDM) and the impact of recombinant human insulin-like growth factor I (rhIGF-I).
    Cheetham TD; Connors M; Clayton K; Watts A; Dunger DB
    Clin Endocrinol (Oxf); 1997 Apr; 46(4):415-24. PubMed ID: 9196603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group.
    Thrailkill KM; Quattrin T; Baker L; Kuntze JE; Compton PG; Martha PM
    Diabetes Care; 1999 Apr; 22(4):585-92. PubMed ID: 10189536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment.
    Carroll PV; Umpleby M; Alexander EL; Egel VA; Callison KV; Sönksen PH; Russell-Jones DL
    Clin Endocrinol (Oxf); 1998 Dec; 49(6):739-46. PubMed ID: 10209561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant IGF-I therapy in insulin-dependent diabetes mellitus.
    Savage MO; Dunger DB
    Diabetes Metab; 1996 Jul; 22(4):257-60. PubMed ID: 8767172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human insulin-like growth factor-I abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type I diabetes mellitus.
    Crowne EC; Samra JS; Cheetham T; Watts A; Holly JM; Dunger DB
    Metabolism; 1998 Jan; 47(1):31-8. PubMed ID: 9440474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of recombinant human insulin-like growth factor I on growth hormone secretion in adolescents with insulin dependent diabetes mellitus.
    Cheetham TD; Clayton KL; Taylor AM; Holly J; Matthews DR; Dunger DB
    Clin Endocrinol (Oxf); 1994 Apr; 40(4):515-22. PubMed ID: 8187319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of IGF-binding proteins in mediating the effects of recombinant human IGF-I on insulin requirements in type 1 diabetes mellitus.
    Crowne EC; Samra JS; Cheetham T; Acerini CL; Watts A; Holly JM; Dunger DB
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3686-91. PubMed ID: 11502796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual hormonal replacement with insulin and recombinant human insulin-like growth factor I in IDDM. Effects on glycemic control, IGF-I levels, and safety profile.
    Quattrin T; Thrailkill K; Baker L; Litton J; Dwigun K; Rearson M; Poppenheimer M; Giltinan D; Gesundheit N; Martha P
    Diabetes Care; 1997 Mar; 20(3):374-80. PubMed ID: 9051390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus.
    Acerini CL; Harris DA; Matyka KA; Watts AP; Umpleby AM; Russell-Jones DL; Dunger DB
    Metabolism; 1998 Dec; 47(12):1481-9. PubMed ID: 9867078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of recombinant human insulin-like growth factor-I (IGF-I) administration on the levels of IGF-I, IGF-II and IGF-binding proteins in adolescents with insulin-dependent diabetes mellitus.
    Cheetham TD; Taylor A; Holly JM; Clayton K; Cwyfan-Hughes S; Dunger DB
    J Endocrinol; 1994 Aug; 142(2):367-74. PubMed ID: 7523562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does recombinant human insulin-like growth factor-1 have a role in the treatment of diabetes?
    Dunger DB; Acerini CL
    Diabet Med; 1997 Sep; 14(9):723-31. PubMed ID: 9300221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates.
    Williams RM; Yuen K; White D; Mallard B; Dalton RN; Acerini CL; Dunger DB
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):439-45. PubMed ID: 16984235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. rhIGF-I administration reduces insulin requirements, decreases growth hormone secretion, and improves the lipid profile in adults with IDDM.
    Carroll PV; Umpleby M; Ward GS; Imuere S; Alexander E; Dunger D; Sönksen PH; Russell-Jones DL
    Diabetes; 1997 Sep; 46(9):1453-8. PubMed ID: 9287046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.